1. INTRODUCTION

1.1. RESEARCH OBJECTIVES

1.2. RESEARCH METHODOLOGY

1.3. RESEARCH PROCESS

1.4. SCOPE AND COVERAGE

1.4.1. Market Definition

1.4.2. Key Questions Answered

1.5. MARKET SEGMENTATION

2. EXECUTIVE SUMMARY

3. MARKET OVERVIEW

4. GROWTH OPPORTUNITIES BY SEGMENT

5. MARKET LANDSCAPE

5.1. PORTER’S FIVE FORCES ANALYSIS

5.1.1. Bargaining Power Of Supplier

5.1.2. Threat Of New Entrants

5.1.3. Threat Of Substitutes

5.1.4. Competitive Rivalry

5.1.5. Bargaining Power Among Buyers

5.2. INDUSTRY VALUE CHAIN ANALYSIS

5.3. MARKET DYNAMICS

5.3.1. Drivers

5.3.2. Restraints

5.3.3. Opportunities

5.3.4. Challenges

5.4. MARKET TREND ANALYSIS

5.5. REGULATORY LANDSCAPE

5.6. PESTLE ANALYSIS

5.7. PRICE TREND ANALYSIS

5.8. PATENT ANALYSIS

5.9. WIRELESS CONNECTIVITY EVALUATION

5.10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR

5.10.1. Geopolitical Market Disruptions

5.10.2. Supply Chain Disruptions

5.10.3. Instability in Emerging Markets

5.11. ECOSYSTEM

6. CAR T-CELL THERAPY MARKET BY PRODUCT (2023-2033)

6.1. CAR T-CELL THERAPY MARKET SNAPSHOT AND GROWTH ENGINE

6.2. MARKET OVERVIEW

6.3. ABECMA (IDECABTAGENE VICLEUCEL)

6.3.1. Introduction And Market Overview

6.3.2. Historic And Forecasted Market Size in Value (2023-2033F)

6.3.3. Historic And Forecasted Market Size in Volume (2023-2033F)

6.3.4. Key Market Trends, Growth Factors and Opportunities

6.3.5. Geographic Segmentation Analysis

6.4. BREYANZI (LISOCABTAGENE MARALEUCEL)

6.5. CARVYKTI (CILTACABTAGENE AUTOLEUCEL)

6.6. KYMRIAH (TISAGENLECLEUCEL)

6.7. TECARTUS (BREXUCABTAGENE AUTOLEUCEL)

6.8. YESCARTA (AXICABTAGENE CILOLEUCEL)

6.9. OTHER PRODUCTS

7. CAR T-CELL THERAPY MARKET BY DISEASE INDICATION (2023-2033)

7.1. CAR T-CELL THERAPY MARKET SNAPSHOT AND GROWTH ENGINE

7.2. MARKET OVERVIEW

7.3. LEUKEMIA

7.3.1. Introduction And Market Overview

7.3.2. Historic And Forecasted Market Size in Value (2023-2033F)

7.3.3. Historic And Forecasted Market Size in Volume (2023-2033F)

7.3.4. Key Market Trends, Growth Factors And Opportunities

7.3.5. Geographic Segmentation Analysis

7.4. LYMPHOMA

7.5. MULTIPLE MYELOMA

7.6. OTHER DISEASE INDICATIONS

8. CAR T-CELL THERAPY MARKET BY END-USE (2023-2033)

8.1. CAR T-CELL THERAPY MARKET SNAPSHOT AND GROWTH ENGINE

8.2. MARKET OVERVIEW

8.3. HOSPITALS

8.3.1. Introduction And Market Overview

8.3.2. Historic And Forecasted Market Size in Value (2023-2033F)

8.3.3. Historic And Forecasted Market Size in Volume (2023-2033F)

8.3.4. Key Market Trends, Growth Factors And Opportunities

8.3.5. Geographic Segmentation Analysis

8.4. CANCER TREATMENT CENTERS

9. COMPANY PROFILES AND COMPETITIVE ANALYSIS

9.1. COMPETITIVE LANDSCAPE

9.1.1. Competitive Benchmarking

9.1.2. CAR T-CELL THERAPY MARKET Share By Manufacturer (2023)

9.1.3. Industry BCG Matrix

9.1.4. Heat Map Analysis

9.1.5. Mergers & Acquisitions

9.2. BRISTOL-MYERS SQUIBB COMPANY

9.2.1. Company Overview

9.2.2. Key Executives

9.2.3. Company Snapshot

9.2.4. Role of the Company in the Market

9.2.5. Sustainability and Social Responsibility

9.2.6. Operating Business Segments

9.2.7. Product Portfolio

9.2.8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)

9.2.9. Key Strategic Moves And Recent Developments

9.2.10. SWOT Analysis

9.3. JOHNSON & JOHNSON SERVICES INC.

9.4. NOVARTIS AG

9.5. JW THERAPEUTICS (SHANGHAI) CO. LTD.

9.6. GILEAD SCIENCES INC.

9.7. JW THERAPEUTICS (SHANGHAI) CO. LTD.

9.8. MERCK & CO. INC.

9.9. SORRENTO THERAPEUTICS INC.

9.10. BLUEBIRD BIO INC.

9.11. SANGAMO THERAPEUTICS

9.12. GSK PLC.

9.13. OTHER KEY PLAYERS

10. GLOBAL CAR T-CELL THERAPY MARKET BY REGION

10.1. OVERVIEW

10.2. NORTH AMERICA

10.2.1. Key Market Trends, Growth Factors And Opportunities

10.2.2. Key Manufacturers

10.2.3. Historic And Forecasted Market Size By PRODUCT

10.2.4. Historic And Forecasted Market Size By DISEASE INDICATION

10.2.5. Historic And Forecasted Market Size By END-USE

10.2.6. Historic And Forecasted Market Size By Country

10.2.6.1. USA

10.2.6.2. Canada

10.2.6.3. Mexico

10.3. EASTERN EUROPE

10.3.1. Key Market Trends, Growth Factors And Opportunities

10.3.2. Key Manufacturers

10.3.3. Historic And Forecasted Market Size By Segments

10.3.4. Historic And Forecasted Market Size By Country

10.3.4.1. Russia

10.3.4.2. Bulgaria

10.3.4.3. The Czech Republic

10.3.4.4. Hungary

10.3.4.5. Poland

10.3.4.6. Romania

10.3.4.7. Rest Of Eastern Europe

10.4. WESTERN EUROPE

10.4.1. Key Market Trends, Growth Factors And Opportunities

10.4.2. Key Manufacturers

10.4.3. Historic And Forecasted Market Size By Segments

10.4.4. Historic And Forecasted Market Size By Country

10.4.4.1. Germany

10.4.4.2. United Kingdom

10.4.4.3. France

10.4.4.4. The Netherlands

10.4.4.5. Italy

10.4.4.6. Spain

10.4.4.7. Rest Of Western Europe

10.5. ASIA PACIFIC

10.5.1. Key Market Trends, Growth Factors And Opportunities

10.5.2. Key Manufacturers

10.5.3. Historic And Forecasted Market Size By Segments

10.5.4. Historic And Forecasted Market Size By Country

10.5.4.1. China

10.5.4.2. India

10.5.4.3. Japan

10.5.4.4. South Korea

10.5.4.5. Malaysia

10.5.4.6. Thailand

10.5.4.7. Vietnam

10.5.4.8. The Philippines

10.5.4.9. Australia

10.5.4.10. New-Zealand

10.5.4.11. Rest Of APAC

10.6. MIDDLE EAST & AFRICA

10.6.1. Key Market Trends, Growth Factors And Opportunities

10.6.2. Key Manufacturers

10.6.3. Historic And Forecasted Market Size By Segments

10.6.4. Historic And Forecasted Market Size By Country

10.6.4.1. Turkey

10.6.4.2. Bahrain

10.6.4.3. Kuwait

10.6.4.4. Saudi Arabia

10.6.4.5. Qatar

10.6.4.6. UAE

10.6.4.7. Israel

10.6.4.8. South Africa

10.7. SOUTH AMERICA

10.7.1. Key Market Trends, Growth Factors And Opportunities

10.7.2. Key Manufacturers

10.7.3. Historic And Forecasted Market Size By Segments

10.7.4. Historic And Forecasted Market Size By Country

10.7.4.1. Brazil

10.7.4.2. Argentina

10.7.4.3. Rest of South America

11. INVESTMENT ANALYSIS

12. ANALYST VIEWPOINT AND CONCLUSION

12.1. Recommendations and Concluding Analysis

12.2. Potential Market Strategies

Report	Car T-Cell Therapy Market
Selected License	Multi ID: IMR1091

Buyer Information

Order Summary